RTP Mobile Logo
Renal Cell Cancer Update Think Tank, Issue 1
Released October 2013

Roundtable participants include Drs Robert A Figlin, Thomas E Hutson, David F McDermott, Robert J Motzer, David I Quinn and Walter Stadler. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Renal cell carcinoma (RCC) is by far the most common primary tumor known to develop within the kidney and renal pelvis. Although RCC may present as diverse histologic subtypes, more than 85% of these are clear cell cancers. Historically, treatment of advanced clear cell RCC — resistant to conventional chemotherapeutics — had been limited to cytokine immunotherapy. Beginning in 2005, this paradigm shifted rapidly and dramatically, culminating in the FDA approval of 7 new therapeutic agents or regimens for advanced-stage disease. Thus, practicing oncologists must maintain current knowledge of the benefits and risks of the multiple acceptable treatment approaches. To bridge the gap between research and patient care, this program features a case-based roundtable discussion with leading investigators to assist medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of RCC with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Identify patient characteristics that may help to distinguish the individualized utility of cytoreductive nephrectomy in the era of effective targeted therapies for metastatic RCC (mRCC).
    • Recall criteria for identification of patients with asymptomatic mRCC who may be suitable for watchful waiting or treatment holidays, and apply these to therapeutic decision-making.
    • Educate patients with mRCC about the safety and tolerability of multikinase VEGF tyrosine kinase inhibitors, mTOR inhibitors and VEGF monoclonal antibody therapy.
    • Recommend supportive measures to enhance the tolerability of targeted therapeutic agents for RCC, including the use of dose reductions, schedule changes or alternative therapies.
    • Apply the results of existing and emerging clinical research to the evidence-based selection of front-line and subsequent therapy for mRCC.
    • Recall the scientific rationale for and efficacy of approved and novel investigational immunotherapeutic agents demonstrating activity in RCC.
    • Counsel appropriately selected patients with RCC about the availability of ongoing clinical trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the audio MP3s, read the text portion, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/RCCUTT113/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FiglinAdvisory Committee: Galena Biopharma, Onyx Pharmaceuticals Inc, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr HutsonAdvisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc; Contracted Research: GlaxoSmithKline, Pfizer Inc; Speakers Bureau: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc, Sanofi. Dr McDermottConsulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Roche Laboratories Inc. Dr MotzerConsulting Agreements: Genentech BioOncology, Pfizer Inc; Contracted Research: Bristol-Myers Squibb Company, Eisai Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr QuinnAdvisory Committee: Amgen Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories Inc, Teva Oncology, Veridex LLC; Paid Research: Millennium: The Takeda Oncology Company, Sanofi; Other Remunerated Activities: Medivation Inc, Teva Oncology. Dr StadlerAdvisory Committee: Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation; Consulting Agreements: Genentech BioOncology, Pfizer Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation and Prometheus Laboratories Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2013
    Expiration date: October 2014

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Renal Cell Cancer Update Think Tank, Issue 1
Released October 2013

Roundtable participants include Drs Robert A Figlin, Thomas E Hutson, David F McDermott, Robert J Motzer, David I Quinn and Walter Stadler. (Audio Content)

Read print: